Dana-Farber Cancer Institute: Immunotherapy Combination Improves Outcomes in Advanced Kidney Cancer
March 04, 2021
March 04, 2021
BOSTON, March 4 (TNSJou) -- The Dana-Farber Cancer Institute issued the following news release:
An immunotherapy agent combined with a tyrosine kinase inhibitor drug significantly improved progression-free survival and reduced the risk of death compared to a single agent treatment in advanced kidney cancer patients, according to first results of a phase 3 clinical trial, CheckMate -9ER, published in the New England Journal of Medicine.
Recently, results from that trial . . .
An immunotherapy agent combined with a tyrosine kinase inhibitor drug significantly improved progression-free survival and reduced the risk of death compared to a single agent treatment in advanced kidney cancer patients, according to first results of a phase 3 clinical trial, CheckMate -9ER, published in the New England Journal of Medicine.
Recently, results from that trial . . .